Previous 10 | Next 10 |
Fluidigm ( FLDM , +13% ) is adding to already strong daily gains as Citron Research reiterates its long on the stock with a price target more than double current levels. More news on: Fluidigm Corporation, Healthcare stocks news, Read more ...
After receiving an emergency use authorization from the Food and Drug Administration (FDA) last month, Fluidigm (NASDAQ: FLDM) reported that its saliva-based test for the novel coronavirus that causes COVID-19 is being run at two Clinical Laboratory Improvement Amendments (CLIA) certified ...
CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm C...
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that ImmunoGenomics, based in metropolitan Houston, an...
Investment Thesis Enzo Biochem, Inc. ( ENZ ) is a vertically integrated life sciences company focusing on developing unique diagnostic platform technologies. Specific to the outbreak of COVID-19, ENZ also provides both molecular and serology tests in New York, New Jersey, and Connecticut. ...
Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry Leading Academic and Pharma Researchers Detail Latest CyTOF Based Discoveries in Infectious Disease, Immunology and the Tumor Microenvironment SOUTH SAN F...
Coronavirus-test manufacturers Becton, Dickinson (NYSE: BDX) , Co-Diagnostics (NASDAQ: CODX) , and Fluidigm (NASDAQ: FLDM) saw their shares move by double-digit percentages in August, according to data provided by S&P Global Market Intelligence . Although the ...
Fluidigm (NASDAQ: FLDM ) has achieved the initial milestone under its letter contract with the National Institutes of Health (NIH), National Institute of Biomedical Imaging and Bioengineering, under the agency’s Rapid Acceleration of Diagnostics ((RADx)) initiative. The ...
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced progress on the Company’s Rapid Acceleration of Diag...
Corbus Pharmaceuticals (NASDAQ: CRBP ) -75% after announcing topline results from RESOLVE-1 study of Lenabasum. More news on: Corbus Pharmaceuticals Holdings, Inc., PolyMet Mining Corp., Tesla, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characteriza...
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of app...